Ipsen Receives CHMP Negative Opinion for Palovarotene as Treatment for Fibrodysplasia

 

• Ipsen to request re-examination of CHMP opinion on palovarotene as a potential treatment for fibrodysplasia ossificans progressiva in E.U.
• FOP is an ultra-rare disease that continuously and permanently causes abnormal bone formation.¹ There are currently no disease-modifying treatment options available in E.U.
• Regulatory processes are continuing in other countries including the U.S.

https://www.biospace.com/article/releases/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u-/